Need professional-grade analysis? Visit stockanalysis.com
$1.64B
3.91
749
N/A
Novavax Inc (NVAX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $8.49, down 3.96% from the previous close.
Over the past year, NVAX has traded between a low of $5.95 and a high of $11.19. The stock has gained 13.7% over this period. It is currently 24.1% below its 52-week high.
Novavax Inc has a market capitalization of $1.64B, with a price-to-earnings ratio of 3.91.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Side-by-side comparison against top Healthcare peers.